Related Experiment Videos

Anti-hCG vaccines are in clinical trials

G P Talwar¹, O Singh, R Pal

¹National Institute of Immunology, New Delhi, India.

Scandinavian Journal of Immunology. Supplement

|January 1, 1992

Abstract:

Two vaccines inducing antibodies against human chorionic gonadotropin (hCG) have completed Phase I clinical trials, indicating the reversibility and safety of these vaccines. One is currently in Phase II efficacy trials in women in three major centres in India. The available data suggest that the vaccine prevents pregnancy above antibody titres of 50 ng/ml hCG bioneutralization capacity.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Survivin targeting triple-fusion vaccine DCSurvivin-LTB inhibits tumor growth in mouse model of triple-negative breast cancer.

Medical oncology (Northwood, London, England)·2025

Expression, purification and characterization of a novel triple fusion protein developed for the immunotherapy of survivin positive cancers.

Protein expression and purification·2024

Humanized recombinant immunotoxin targeting hCG demonstrates therapeutic potential for advanced stage difficult to treat cancers.

Journal of drug targeting·2024

Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model.

World journal of clinical oncology·2019

Immunotherapy approach with recombinant survivin adjuvanted with alum and MIP suppresses tumor growth in murine model of breast cancer.

Preparative biochemistry & biotechnology·2018

Development of a novel recombinant LHRH fusion protein for therapy of androgen and estrogen dependent cancers.

Protein expression and purification·2017

See all related articles